Incorporating VEGF-targeted therapy in advanced urothelial cancer

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Urinary tract cancer survival in Europe 1999–2007: Results of the population-based study EUROCARE-5

(2015) Rafael Marcos-Gragera et al.   EUROPEAN JOURNAL OF CANCER

SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma

(2015) Thomas Geldart et al.   EUROPEAN UROLOGY

Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma.

(2015) Daniel Peter Petrylak et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer.

(2015) Sandy Srinivas et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy

(2013) Holger Gerullis et al.   ANTI-CANCER DRUGS

Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)

(2013) Susanne Krege et al.   BJU INTERNATIONAL

Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells

(2013) M Santoni et al.   BRITISH JOURNAL OF CANCER

A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer

(2013) Roberto Pili et al.   Clinical Genitourinary Cancer

Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer

(2013) Arjun V. Balar et al.   JOURNAL OF CLINICAL ONCOLOGY

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer

(2012) Matthew D. Galsky et al.   Clinical Genitourinary Cancer

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial

(2012) Andrea Necchi et al.   LANCET ONCOLOGY

Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder

(2012) APOSTOLOS ZARAVINOS et al.   ONCOLOGY REPORTS

Sunitinib Malate Provides Activity Against Murine Bladder Tumor Growth and Invasion in a Preclinical Orthotopic Model

(2012) Eddie Shu-yin Chan et al.   UROLOGY

Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer

(2012) Sabrina Thalita Reis et al.   BMC Urology

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

(2011) J. Bellmunt et al.   ANNALS OF ONCOLOGY

Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75

(2011) Noah M. Hahn et al.   JOURNAL OF CLINICAL ONCOLOGY

Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer

(2011) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

(2010) Srikala S. Sridhar et al.   INVESTIGATIONAL NEW DRUGS

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

(2010) Roy S Herbst et al.   LANCET ONCOLOGY

Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

(2010) Przemyslaw Twardowski et al.   UROLOGY

Phase 2 trial of sorafenib in patients with advanced urothelial cancer

(2009) Robert Dreicer et al.   CANCER

Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions

(2009) A. Morabito et al.   ONCOLOGIST

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

(2008) Guru Sonpavde et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Hypoxia-inducible factor-1  expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma

(2007) C-Y Chai et al.   JOURNAL OF CLINICAL PATHOLOGY